News – March 7, 2006

07
Mar

Patent issues for 'System and method for processing bone marrow'; Enhances BioAccess Marrow Collection Kit Technology

BioAccess announced the United States Patent 7,008,394 issued on March 7, 2006. The issued patent is an initial patent supporting the platform for the BioAccess Bone Marrow Collection Kit. The company believes this is a significant initial intellectual property milestone in the company's products relating to access of bone marrow cavities and bone marrow collection.

The company's present Bone Marrow Collection Kit dramatically improved the methods used in the aspiration and collection of bone marrow. The Bone Marrow Collection Kit was the first system to be a 'Sealed System' and the first system recognized as a 'Safety Device' by EPINet, Cal/OSHA and Frontline Healthcare Workers Safety Project. The Sealed Bone Marrow Collection Kit is comprised of a sealed collection container and additional sealed secondary containers. The proprietary configuration allowed for the elimination of several steps of significant advantage, such as docking syringes or spraying marrow.

"This will strengthen our present Marrow Collection System position and we are pleased with the issuance of the patent," said Robert Chapolini, MD, President. "The present foundation for our initial product, the BioAccess Sealed Bone Marrow Collection Kit has been dramatically improved along with our potential additional products as we look towards the recent expansion within the market. We see an expanded use of progenitor cells for expansion, cell concentration, cell grafting in various applications such as bone graft, non-union, other orthopedic applications, circulatory, cardiovascular, neurology, and research."

"Adding the issued patent to the already superior Marrow Collection Kit is a highlight for BioAccess," commented Russell Geise, Vice President of Research and Development. "BioAccess also feels confident it can support improved devices in the growing market of bone marrow aspiration of stem cells with the intellectual property and design superiority of the current BioAccess technology. Initial results of stem cells in orthopedic research of non-unions and bone grafting along with the results of the progenitor cells such as CD34+ and CD133+ in the cardiology field will allow BioAccess to assist the physicians with proprietary and ergonomically superior devices."

The BioAccess intellectual property pertaining to surgical drills, surgical power tools, bone marrow collection, and medical packaging continues to grow. This document contains forward-looking statements, including without limitation, statements concerning planned product development objectives, potential product applications, and potential advantages of BioAccess products or planned products. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties. Actual results to differ materially from the statements contained herein. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. BioAccess undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. BioAccess is a privately owned medical device company incorporated in Delaware. Nothing on this page or site should be construed as an offer or solicitation to buy or sell any specific products or securities.